Holen Sie sich die Stockscreener-App
3.19
5.34%
-0.18
Schlusskurs vom Vortag:
$3.37
Offen:
$3.46
24-Stunden-Volumen:
74,293
Relative Volume:
2.69
Marktkapitalisierung:
$10.24M
Einnahmen:
$556.00K
Nettoeinkommen (Verlust:
$-5.28M
KGV:
-1.4907
EPS:
-2.14
Netto-Cashflow:
$-6.23M
1W Leistung:
+0.31%
1M Leistung:
+8.14%
6M Leistung:
+8.14%
1J Leistung:
-4.78%
1-Tages-Spanne:
$3.11
$3.5999
1-Wochen-Bereich:
$2.79
$3.70
52-Wochen-Spanne:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Firmenname
Cyclerion Therapeutics Inc
Sektor
Branche
Telefon
617-621-7722
Adresse
301 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie CYCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.19 | 11.32M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-20 | Eingeleitet | Truist | Buy |
| 2021-09-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-03 | Eingeleitet | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Aktie (CYCN) Neueste Nachrichten
What drives Cyclerion Therapeutics Inc. stock priceExceptional growth trajectory - jammulinksnews.com
Cyclerion Therapeutics Inc. Stock Analysis and ForecastTriple-digit wealth increases - jammulinksnews.com
Robin Energy Ltd. Stock Analysis and ForecastRapid growth opportunities - Autocar Professional
What analysts say about Cyclerion Therapeutics Inc. stockRapid return acceleration - Autocar Professional
HSPO Stock Analysis and ForecastFree Consultation - jammulinksnews.com
Is Cyclerion Therapeutics Inc. a good long term investmentPhenomenal returns - jammulinksnews.com
What analysts say about ADIL stockDynamic capital growth - jammulinksnews.com
Is GTSG a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
ENTO Stock Analysis and ForecastUnprecedented profits - jammulinksnews.com
Is Columbus McKinnon Corporation a good long term investmentConsistent triple returns - jammulinksnews.com
Is DBVT a good long term investmentUnprecedented profits - jammulinksnews.com
How Cyclerion Therapeutics Inc. stock performs during market volatilityGrowth Stock Monitor - beatles.ru
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 3.6% – Time to Sell? - Defense World
Why Cyclerion Therapeutics Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
FIB(fib)Low Risk Stock Strategies - Newser
What makes Cyclerion Therapeutics Inc. stock price move sharplySmart Return Focused Trading - Newser
What makes PotlatchDeltic Corporation stock price move sharplyFree Access to Investment Community - Newser
How United Parcel Service Inc. stock performs during market volatilityFree VIP Group - Newser
What makes Sight Sciences Inc. stock price move sharply2x Return Forecast - Newser
Cyclerion Therapeutics (NASDAQ:CYCN) Stock Price Down 2.4% – Here’s Why - Defense World
Cyclerion Therapeutics Gains Shareholder Support at Annual Meeting - TipRanks
Cyclerion Therapeutics (NASDAQ:CYCN) Trading 6.5% Higher – Time to Buy? - Defense World
Regina Graul, Ph.D., Promoted to Chief Executive Officer - marketscreener.com
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer - GlobeNewswire
Renaissance Technologies LLC Invests $34,000 in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) - Defense World
Cyclerion partners with Guggenheim for $20M stock sale By Investing.com - Investing.com Nigeria
Cyclerion partners with Guggenheim for $20M stock sale - Investing.com Australia
Cyclerion Therapeutics Enters $20M Sales Agreement - TipRanks
CYCN: Company Stock Sale Proceeds Exclude Firm's Benefit | CYCN Stock News - GuruFocus
Finanzdaten der Cyclerion Therapeutics Inc-Aktie (CYCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):